Evidence map›Paper›PMID 42353207›Full record

ArticleInternational journal of molecular sciences2026

Solution Structure of Nucleoprotein Domain 1 from the Emerging Yezo Virus.

Anastasia V Gladysheva, Alexey O Yanshin, Nikita S Radchenko, Irina A Osinkina, Egor O Ukladov, Alexander P Agafonov

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anastasia V GladyshevaState Research Center of Virology and Biotechnology "Vector", 630559 Kol'tsovo, Russia.ORCID 0000-0002-7396-3954
Alexey O YanshinState Research Center of Virology and Biotechnology "Vector", 630559 Kol'tsovo, Russia.
Nikita S RadchenkoState Research Center of Virology and Biotechnology "Vector", 630559 Kol'tsovo, Russia.ORCID 0009-0002-9524-9062
Irina A OsinkinaState Research Center of Virology and Biotechnology "Vector", 630559 Kol'tsovo, Russia.ORCID 0009-0009-6942-0840
Egor O UkladovScientific Educational Center of the Institute of Chemical Technology, Novosibirsk State University, 630090 Novosibirsk, Russia.
Alexander P AgafonovState Research Center of Virology and Biotechnology "Vector", 630559 Kol'tsovo, Russia.ORCID 0000-0003-2577-0434

Funding

The Ministry of Education and Science of the Russian Federation agreement No. 075-15-2025-452
6 · The paper itself

Abstract

The Yezo virus (YEZV) is a recently discovered tick-borne orthonairovirus with pathogenic potential, causing acute febrile illness in humans. Viral nucleoproteins (N) play a key role in genome packaging, replication, and modulation of host immune responses, making their structural characterization essential for understanding viral pathogenesis and developing targeted countermeasures. However, the absence of structural data for YEZV proteins significantly hinders these efforts. This study presents the first solution structure of the YEZV N domain 1 (D1). A highly purified, soluble, tag-free recombinant YEZV N D1 was produced from the native sequence of the clinical YEZV isolate. The native-state conformation was resolved through an integrated approach combining size-exclusion chromatography coupled with small-angle X-ray scattering (SEC-SAXS), AlphaFold 3 structure prediction, and all-atom molecular dynamics simulations. The YEZV N D1 structure adopts a stable, predominantly α-helical globular fold that remains monomeric under near-physiological conditions. SEC-SAXS data show excellent agreement with computational models, revealing moderate conformational flexibility. The characterized recombinant YEZV N D1 and its first solution structure reported here providing essential insights into understanding of YEZV molecular architecture. These findings lay a foundation for rational serological assay development and structure-guided therapeutic design against this and other emerging orthonairoviruses.

Indexed as

NucleoproteinsViral ProteinsAmino Acid SequenceHumansModels, MolecularMolecular Dynamics SimulationProtein DomainsScattering, Small AngleX-Ray DiffractionNucleoproteinsViral ProteinsIxodid tickNairoviridaeOrthonairovirusprotein structureribonucleoprotein complexRNA virussmall-angle X-ray scatteringtick-borne virusviral protein

Identifiers

PMID42353207
PMCPMC13300033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.